This HTML5 document contains 209 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n17http://linked.opendata.cz/resource/AHFS/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00423/identifier/wikipedia/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/drugbank/company/
n23http://linked.opendata.cz/resource/drugbank/dosage/
n6http://linked.opendata.cz/resource/drugbank/drug/DB00423/identifier/pharmgkb/
n13http://linked.opendata.cz/resource/drugbank/mixture/
n19http://www.drugs.com/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00423/identifier/pubchem-compound/
n18http://bio2rdf.org/drugbank:
n28http://linked.opendata.cz/resource/drugbank/drug/DB00423/identifier/pubchem-substance/
admshttp://www.w3.org/ns/adms#
n26http://linked.opendata.cz/resource/drugbank/drug/DB00423/identifier/kegg-drug/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00423/identifier/drugbank/
n16http://www.rxlist.com/cgi/generic/
n9http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n27http://linked.opendata.cz/resource/drugbank/drug/DB00423/identifier/national-drug-code-directory/
n10http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n14http://linked.opendata.cz/resource/drugbank/property/
n20http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n24http://linked.opendata.cz/resource/drugbank/drug/DB00423/identifier/chemspider/
n12http://linked.opendata.cz/resource/atc/
n11http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00423
rdf:type
n3:Drug
n3:description
A centrally acting muscle relaxant whose mode of action has not been established. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1206)
n3:dosage
n23:271B4A9A-363D-11E5-9242-09173F13E4C5 n23:271B4A9F-363D-11E5-9242-09173F13E4C5 n23:271B4A9B-363D-11E5-9242-09173F13E4C5 n23:271B4A9C-363D-11E5-9242-09173F13E4C5 n23:271B4A9D-363D-11E5-9242-09173F13E4C5 n23:271B4A9E-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Sica DA, Comstock TJ, Davis J, Manning L, Powell R, Melikian A, Wright G: Pharmacokinetics and protein binding of methocarbamol in renal insufficiency and normals. Eur J Clin Pharmacol. 1990;39(2):193-4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2253675
n3:group
approved
n3:halfLife
1.14-1.24 hours
n3:indication
For use as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions.
n3:manufacturer
n4:271B4A88-363D-11E5-9242-09173F13E4C5 n4:271B4A83-363D-11E5-9242-09173F13E4C5 n4:271B4A84-363D-11E5-9242-09173F13E4C5 n4:271B4A81-363D-11E5-9242-09173F13E4C5 n4:271B4A82-363D-11E5-9242-09173F13E4C5 n4:271B4A87-363D-11E5-9242-09173F13E4C5 n4:271B4A85-363D-11E5-9242-09173F13E4C5 n4:271B4A86-363D-11E5-9242-09173F13E4C5 n4:271B4A73-363D-11E5-9242-09173F13E4C5 n4:271B4A74-363D-11E5-9242-09173F13E4C5 n4:271B4A77-363D-11E5-9242-09173F13E4C5 n4:271B4A78-363D-11E5-9242-09173F13E4C5 n4:271B4A75-363D-11E5-9242-09173F13E4C5 n4:271B4A76-363D-11E5-9242-09173F13E4C5 n4:271B4A7B-363D-11E5-9242-09173F13E4C5 n4:271B4A7C-363D-11E5-9242-09173F13E4C5 n4:271B4A79-363D-11E5-9242-09173F13E4C5 n4:271B4A7A-363D-11E5-9242-09173F13E4C5 n4:271B4A7F-363D-11E5-9242-09173F13E4C5 n4:271B4A80-363D-11E5-9242-09173F13E4C5 n4:271B4A7D-363D-11E5-9242-09173F13E4C5 n4:271B4A7E-363D-11E5-9242-09173F13E4C5 n4:271B4A8D-363D-11E5-9242-09173F13E4C5 n4:271B4A8E-363D-11E5-9242-09173F13E4C5 n4:271B4A8B-363D-11E5-9242-09173F13E4C5 n4:271B4A8C-363D-11E5-9242-09173F13E4C5 n4:271B4A91-363D-11E5-9242-09173F13E4C5 n4:271B4A92-363D-11E5-9242-09173F13E4C5 n4:271B4A8F-363D-11E5-9242-09173F13E4C5 n4:271B4A90-363D-11E5-9242-09173F13E4C5 n4:271B4A89-363D-11E5-9242-09173F13E4C5 n4:271B4A8A-363D-11E5-9242-09173F13E4C5
owl:sameAs
n9:DB00423 n18:DB00423
dcterms:title
Methocarbamol
adms:identifier
n6:PA164749506 n7:Methocarbamol n22:DB00423 n24:3964 n25:4107 n26:D00402 n27:0781-1760-01 n28:46507761
n3:mechanismOfAction
The mechanism of action of methocarbamol in humans has not been established, but may be due to central nervous system depression. It has no direct action on the contractile mechanism of striated muscle, the motor end plate or the nerve fiber.
n3:packager
n4:271B4A50-363D-11E5-9242-09173F13E4C5 n4:271B4A51-363D-11E5-9242-09173F13E4C5 n4:271B4A4E-363D-11E5-9242-09173F13E4C5 n4:271B4A4F-363D-11E5-9242-09173F13E4C5 n4:271B4A4C-363D-11E5-9242-09173F13E4C5 n4:271B4A4D-363D-11E5-9242-09173F13E4C5 n4:271B4A4A-363D-11E5-9242-09173F13E4C5 n4:271B4A4B-363D-11E5-9242-09173F13E4C5 n4:271B4A48-363D-11E5-9242-09173F13E4C5 n4:271B4A49-363D-11E5-9242-09173F13E4C5 n4:271B4A46-363D-11E5-9242-09173F13E4C5 n4:271B4A47-363D-11E5-9242-09173F13E4C5 n4:271B4A44-363D-11E5-9242-09173F13E4C5 n4:271B4A45-363D-11E5-9242-09173F13E4C5 n4:271B4A32-363D-11E5-9242-09173F13E4C5 n4:271B4A33-363D-11E5-9242-09173F13E4C5 n4:271B4A42-363D-11E5-9242-09173F13E4C5 n4:271B4A43-363D-11E5-9242-09173F13E4C5 n4:271B4A40-363D-11E5-9242-09173F13E4C5 n4:271B4A41-363D-11E5-9242-09173F13E4C5 n4:271B4A3E-363D-11E5-9242-09173F13E4C5 n4:271B4A3F-363D-11E5-9242-09173F13E4C5 n4:271B4A3C-363D-11E5-9242-09173F13E4C5 n4:271B4A3D-363D-11E5-9242-09173F13E4C5 n4:271B4A3A-363D-11E5-9242-09173F13E4C5 n4:271B4A3B-363D-11E5-9242-09173F13E4C5 n4:271B4A38-363D-11E5-9242-09173F13E4C5 n4:271B4A39-363D-11E5-9242-09173F13E4C5 n4:271B4A36-363D-11E5-9242-09173F13E4C5 n4:271B4A37-363D-11E5-9242-09173F13E4C5 n4:271B4A34-363D-11E5-9242-09173F13E4C5 n4:271B4A35-363D-11E5-9242-09173F13E4C5 n4:271B4A2E-363D-11E5-9242-09173F13E4C5 n4:271B4A2F-363D-11E5-9242-09173F13E4C5 n4:271B4A2C-363D-11E5-9242-09173F13E4C5 n4:271B4A2D-363D-11E5-9242-09173F13E4C5 n4:271B4A71-363D-11E5-9242-09173F13E4C5 n4:271B4A72-363D-11E5-9242-09173F13E4C5 n4:271B4A54-363D-11E5-9242-09173F13E4C5 n4:271B4A55-363D-11E5-9242-09173F13E4C5 n4:271B4A52-363D-11E5-9242-09173F13E4C5 n4:271B4A53-363D-11E5-9242-09173F13E4C5 n4:271B4A30-363D-11E5-9242-09173F13E4C5 n4:271B4A5F-363D-11E5-9242-09173F13E4C5 n4:271B4A31-363D-11E5-9242-09173F13E4C5 n4:271B4A60-363D-11E5-9242-09173F13E4C5 n4:271B4A5D-363D-11E5-9242-09173F13E4C5 n4:271B4A5E-363D-11E5-9242-09173F13E4C5 n4:271B4A5B-363D-11E5-9242-09173F13E4C5 n4:271B4A5C-363D-11E5-9242-09173F13E4C5 n4:271B4A59-363D-11E5-9242-09173F13E4C5 n4:271B4A5A-363D-11E5-9242-09173F13E4C5 n4:271B4A57-363D-11E5-9242-09173F13E4C5 n4:271B4A58-363D-11E5-9242-09173F13E4C5 n4:271B4A56-363D-11E5-9242-09173F13E4C5 n4:271B4A6F-363D-11E5-9242-09173F13E4C5 n4:271B4A70-363D-11E5-9242-09173F13E4C5 n4:271B4A6D-363D-11E5-9242-09173F13E4C5 n4:271B4A6E-363D-11E5-9242-09173F13E4C5 n4:271B4A6B-363D-11E5-9242-09173F13E4C5 n4:271B4A6C-363D-11E5-9242-09173F13E4C5 n4:271B4A69-363D-11E5-9242-09173F13E4C5 n4:271B4A6A-363D-11E5-9242-09173F13E4C5 n4:271B4A67-363D-11E5-9242-09173F13E4C5 n4:271B4A68-363D-11E5-9242-09173F13E4C5 n4:271B4A65-363D-11E5-9242-09173F13E4C5 n4:271B4A66-363D-11E5-9242-09173F13E4C5 n4:271B4A63-363D-11E5-9242-09173F13E4C5 n4:271B4A64-363D-11E5-9242-09173F13E4C5 n4:271B4A61-363D-11E5-9242-09173F13E4C5 n4:271B4A62-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Small amounts of unchanged methocarbamol also are excreted in the urine.
n3:synonym
Methocarbamolum Metocarbamol Méthocarbamol Delaxin Methocarbamol Metocarbamolo (RS)-2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate Robaxin
n3:toxicity
Symptoms of overdose include blurred vision, coma, drowsiness, low blood pressure, nausea, and seizures.
n11:hasAHFSCode
n17:12-20-00
n3:foodInteraction
Avoid alcohol. Take without regard to meals.
n3:mixture
n13:271B4A16-363D-11E5-9242-09173F13E4C5 n13:271B4A17-363D-11E5-9242-09173F13E4C5 n13:271B4A14-363D-11E5-9242-09173F13E4C5 n13:271B4A15-363D-11E5-9242-09173F13E4C5 n13:271B4A1A-363D-11E5-9242-09173F13E4C5 n13:271B4A1B-363D-11E5-9242-09173F13E4C5 n13:271B4A18-363D-11E5-9242-09173F13E4C5 n13:271B4A19-363D-11E5-9242-09173F13E4C5 n13:271B4A1E-363D-11E5-9242-09173F13E4C5 n13:271B4A1F-363D-11E5-9242-09173F13E4C5 n13:271B4A1C-363D-11E5-9242-09173F13E4C5 n13:271B4A1D-363D-11E5-9242-09173F13E4C5 n13:271B4A22-363D-11E5-9242-09173F13E4C5 n13:271B4A23-363D-11E5-9242-09173F13E4C5 n13:271B4A20-363D-11E5-9242-09173F13E4C5 n13:271B4A21-363D-11E5-9242-09173F13E4C5 n13:271B4A27-363D-11E5-9242-09173F13E4C5 n13:271B4A28-363D-11E5-9242-09173F13E4C5 n13:271B4A24-363D-11E5-9242-09173F13E4C5 n13:271B4A25-363D-11E5-9242-09173F13E4C5 n13:271B4A2B-363D-11E5-9242-09173F13E4C5 n13:271B4A29-363D-11E5-9242-09173F13E4C5 n13:271B4A2A-363D-11E5-9242-09173F13E4C5 n13:271B4A26-363D-11E5-9242-09173F13E4C5
foaf:page
n16:methocar.htm n19:methocarbamol.html n20:rob1384.shtml
n3:IUPAC-Name
n14:271B4AA4-363D-11E5-9242-09173F13E4C5
n3:InChI
n14:271B4AAA-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n14:271B4AA9-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n14:271B4AA6-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n14:271B4AA7-363D-11E5-9242-09173F13E4C5
n3:SMILES
n14:271B4AA8-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n14:271B4AA2-363D-11E5-9242-09173F13E4C5 n14:271B4ABA-363D-11E5-9242-09173F13E4C5
n3:logP
n14:271B4AA0-363D-11E5-9242-09173F13E4C5 n14:271B4AA3-363D-11E5-9242-09173F13E4C5 n14:271B4ABC-363D-11E5-9242-09173F13E4C5
n3:logS
n14:271B4AA1-363D-11E5-9242-09173F13E4C5
n11:hasATCCode
n12:M03BA03
n3:H-Bond-Acceptor-Count
n14:271B4AB0-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n14:271B4AB1-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n14:271B4AAB-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n14:271B4AAC-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n14:271B4AAE-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n14:271B4AAD-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n14:271B4AAF-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapid. Onset of action is about 30 minutes after oral administration.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
532-03-6
n3:category
n3:clearance
* 0.2 – 0.8 L/h/kg [healthy]
n3:containedIn
n10:271B4A99-363D-11E5-9242-09173F13E4C5 n10:271B4A97-363D-11E5-9242-09173F13E4C5 n10:271B4A98-363D-11E5-9242-09173F13E4C5 n10:271B4A95-363D-11E5-9242-09173F13E4C5 n10:271B4A96-363D-11E5-9242-09173F13E4C5 n10:271B4A93-363D-11E5-9242-09173F13E4C5 n10:271B4A94-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n14:271B4AB6-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n14:271B4AB8-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n14:271B4AB9-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n14:271B4ABB-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n14:271B4AB5-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n14:271B4AB4-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n14:271B4AB7-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n14:271B4AA5-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n14:271B4AB2-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n14:271B4AB3-363D-11E5-9242-09173F13E4C5